We’re thrilled to announce that mycoBiologics has been selected for Stage I support and added to the INCATE portfolio!
The INCATE Selection Committee recognized the potential of our patient-derived human monoclonal antibodies to revolutionize anti-infective drug development. We’re honored to join the INCATE family and work alongside other innovative companies in the fight against infectious diseases.
mycoBiologics is dedicated to developing safer and more effective treatments. Stay tuned for updates on our progress! #INCATE #mycoBiologics #antiinfectives #monoclonalantibodies #drugdevelopment